What is the revenue and EPS growth rate for Albertsons year over year?

What is Albertsons's latest dividend and current dividend yield?

What guidance did Albertsons's management provide for the next earnings period?

What were the key takeaways from Albertsons's earnings call?

What does Albertsons do and what are its main business segments?

What is the market's earnings forecast for Albertsons next quarter?

What factors drove the changes in Albertsons's revenue and profit?

What is Albertsons's gross profit margin?

- **Revenue Resilience**: 2.4% identical sales growth and 21% digital sales surge despite macro challenges.
- **AI-Driven Innovation**: Ask AI increased basket size by 10%, AI assistants enhance personalization, and AI optimizes merchandising and labor.
- **Pharmacy Momentum**: 18% sales growth from immunizations and GLP-1 therapies, with no EBITDA impact from Medicare drug price changes.
- **Financial Discipline**: 33 basis point SG&A improvement, $1.5 billion productivity plan on track, and disciplined capital allocation.
- **Digital Profitability**: Digital sales nearing profitability in 2026, with 50% orders delivered in under 3 hours.
- **Consumer Insights**: Low-income focus on essentials, middle-income trade-down, high-income stable but value-conscious.

**【CEO Summary Section】**
- Delivered 2.4% identical sales growth and 21% digital sales increase, despite external headwinds like government shutdowns and SNAP delays.
- Emphasized AI-driven transformation across customer experience, merchandising, labor optimization, and supply chain.
- Highlighted Ask AI search capability, which increased basket size by 10%, and AI-powered shopping assistants for personalized experiences.
- Accelerated execution in pharmacy (18% sales growth) and loyalty program (12% membership growth to 49 million).
- Targeted price investments in key categories, with sequential improvement in unit trends.
- Announced $1.5 billion productivity plan over 3 years through automation, analytics, and process redesign.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $1.039 billion and adjusted EPS of $0.72, in line with expectations.
- Gross margin decline of 55 basis points (YoY) due to digital and pharmacy mix shifts, partially offset by productivity gains.
- Selling, general, and administrative (SG&A) expense rate improved 33 basis points (YoY) to 4.9%, reflecting disciplined cost management.
- Capital expenditures of $462 million focused on AI, digital transformation, and store upgrades.
- Completed $750 million accelerated share repurchase program, with $1.3 billion remaining under authorization.
- Net debt to adjusted EBITDA ratio of 2.29x, demonstrating financial strength.
- Refinanced $1.5 billion in debt to extend maturity and reduce refinancing risk.

**【Q&A Highlights】**
- **Pricing Strategy**: Surgical price investments in essentials and loyalty programs drove unit growth, with 10% basket size increase for AI users.
- **Pharmacy Growth**: Immunization and GLP-1 therapy adoption fueled 18% sales growth, with no EBITDA impact from Medicare drug price changes.
- **Digital Profitability**: Digital sales penetration at 9.5%, with 50% of orders delivered in under 3 hours, nearing profitability in 2026.
- **Productivity**: $1.5 billion productivity plan on track, with AI embedding across merchandising, labor, and supply chain.
- **Consumer Trends**: Low-income customers focused on essentials, middle-income showed trade-down, high-income remained stable but value-conscious.
- **Real Estate Strategy**: Evaluating underperforming stores for closure or repurposing, with focus on high-density markets for growth.

Albertsons Companies, Inc.(ACI)-20260107-2026 Q3 Earnings call transcript

- **Strategic Reboot**: CEO Susan Morris unveils 'new day' strategy with 2.2% Q2 sales growth, 23% e-commerce surge, and 19% pharmacy expansion.
- **Share Buyback**: $750M ASR (12%+ shares) signals confidence, despite 2.2x net debt/EBITDA ratio.
- **Digital Leap**: AI tools like 'Ask AI' drive 30M+ monthly interactions, e-commerce near breakeven with store-based fulfillment.
- **Pharmacy Power**: 19% growth from GLP-1, script gains, and 3x vaccine market share, but EBITDA dilution persists.
- **Productivity Push**: $1.5B savings (SG&A rate down 50bps) offset price investments, India/Manila tech hubs accelerate cost cuts.

Albertsons Companies, Inc. (ACI) Q2 2026 Earnings Call Transcript

- **Topline Growth**: ID sales +2.8% Q1, driven by 25% e-commerce and 20% pharmacy growth. Q2 ID sales expected at lower end of 2%-2.75% range.
- **Digital Momentum**: E-commerce near breakeven, loyalty members +14% to 47M. Pharmacy cross-shoppers visit 4x more and spend more on groceries.
- **Profitability Focus**: Gross margin down 85bps due to customer value investments, but S&A expense rate improved 63bps. 2025 EBITDA guidance unchanged at $3.8-$3.9B.
- **Future Outlook**: FY26 target: ID sales >2%, EBITDA growth higher than sales. Productivity initiatives to deliver $1.5B savings by 2027.

**【CEO Opening Remarks】**
- **Revenue Performance**: ID sales grew 2.8% YoY, driven by 25% e-commerce growth (9% of total grocery revenue) and 20% pharmacy sales growth. Adjusted EBITDA was $1.11 billion, and adjusted EPS was $0.55.
- **Digital Platforms**: 
  - **E-commerce**: Near breakeven, with features like 'shop assist' enabling customer-associate communication. First-party business led growth.
  - **Loyalty Program**: 14% member growth to 47 million, with 30% engaged households using cashback options.
  - **Pharmacy & Health**: 20% YoY growth, cross-shoppers visit 4x more and spend more on groceries. Central fill facilities reduce costs.
  - **Mobile App**: Used 3x weekly, with tools for meal planning and in-store navigation.
- **Strategic Priorities**: Customer value through price, promotions, and own brands (25.7% penetration). Productivity initiatives to deliver $1.5 billion savings by 2027.

**【CFO Financial Commentary】**
- **Q1 Financials**: GAAP net income $420M, Non-GAAP EPS $0.55. Gross margin rate 27.1% (-85bps YoY) due to customer value investments. S&A expense rate improved 63bps to 17.9%.
- **Capital Allocation**: $585M in capex (3 new stores, 36 remodels), $401M returned to shareholders (including $315M buybacks). Net debt/EBITDA 1.96x.
- **2025 Outlook**: 
  - ID sales 2%-2.75% (up from 1.5%-2.5%), with Q2 at lower end of range.
  - Adjusted EBITDA $3.8-$3.9B, EPS $2.03-$2.16. Tax rate 23.5%-24.5%.
  - FY26 target: ID sales >2%, EBITDA growth higher than sales.

**【Q&A Highlights】**
- **Gross Margin**: Investments in customer value (price, loyalty) drove margin decline. Productivity (national buying, automation) expected to offset in H2.
- **E-commerce Profitability**: Near breakeven, driven by volume leverage, labor efficiency, and transportation optimization.
- **Pharmacy Growth**: Outpaces grocery, with 50% of scripts from new customers. Focus on generics, test-and-treat, and immunizations.
- **Consumer Trends**: Shift to value (e.g., pork, deli chicken), own brands (Chef's Counter launch). SNAP impact minimal due to low penetration.
- **Union Contracts**: Agreements cover ~50% of 120K associates, with wage increases and operational flexibility.

Albertsons Companies, Inc. (ACI) Q1 2025 Earnings Call Transcript

- **Digital Growth Acceleration**: E-commerce penetration at 8% (top markets >10%), Pharmacy revenue up 18%, and loyalty members +15% YoY.
- **FY25 Financial Targets**: Adjusted EBITDA $3.8B-$3.9B, EPS $2.03-$2.16, with 2%+ ID sales growth by FY26.
- **Investment Priorities**: $1.5B productivity savings reinvested in customer value, digital platforms, and health initiatives.
- **Key Risks**: Margin pressure from Pharmacy mix and digital delivery costs, wage inflation (2%-3% expected), and macro demand uncertainty.

**【CEO Summary Section】**
- CEO Vivek Sankaran highlighted the success of the 'Customers for Life' strategy, emphasizing digital growth (E-commerce penetration at 8%), Pharmacy revenue growth (18% YoY), and loyalty program expansion (15% YoY member growth).
- The company is reinvesting $1.5 billion in productivity savings into customer value propositions, digital platforms, and health initiatives.
- FY25 ID sales growth expected in 1.5%-2.5% range, with gradual improvement in grocery sales trends and EBITDA growth exceeding 2% in FY26.

**【CFO Financial Commentary】**
- Q4 2024: Adjusted EBITDA of $855M, adjusted EPS of $0.46, and ID sales growth of 2.3% driven by Pharmacy (18% YoY) and E-commerce (24% YoY).
- FY25 Outlook: Adjusted EBITDA $3.8B-$3.9B, adjusted EPS $2.03-$2.16, and 53-week impact of $65M EBITDA and $0.03 EPS.
- Margins impacted by Pharmacy mix and digital delivery costs, but offset by productivity savings and cost control.

**【Q&A Key Highlights】**
- **Price Investments**: Surgical adjustments by market/category to balance value and margin, with tools to optimize elasticity and sales.
- **Tariffs**: 90%+ of COGS sourced domestically, but ongoing task force to mitigate ingredient-level impacts.
- **Digital Profitability**: E-commerce penetration below peers (8% vs. industry), but scaling to leverage picking efficiency and batch processing.
- **Share Repurchases**: $2B buyback program with $1.9B remaining, assuming $0.06 EPS accretion annually.
- **Pharmacy Growth**: GLP-1 scripts driving short-term dilution but long-term customer engagement in fresh and supplements.
- **AMC Expansion**: 2025 focus on partnerships and dynamic measurement models to grow faster than retail media market.

Albertsons Companies (ACI)-15 Apr 25-2025 Q4 Earnings call transcript

- **Digital Growth Accelerating**: E-commerce penetration at 7% (top market 9%), pharmacy sales at 11% of revenue, and 44.3M loyalty members (+15%). 
- **Productivity Payoff**: $1.5B cost savings target to offset inflation, with 30% of distribution automated by 2025. 
- **Financial Outlook Improved**: Adjusted EBITDA raised to $3.95-3.99B, EPS to $2.25-2.31, driven by productivity and digital growth. 
- **Media Collective Momentum**: AMC growing faster than market, leveraging 4 digital platforms for targeted campaigns. 
- **Key Risks**: Pharmacy mix and digital costs pressure gross margin, but 25% dividend increase signals confidence. 


**【CEO Strategic Overview】**
- **Digital Growth Platforms**: E-commerce penetration at 7% of grocery revenue (top market at 9%), driven by mobile app enhancements and Drive Up & Go services. Pharmacy sales at 11% of total revenue, with Sincerely Health platform reaching 1M users. 
- **Customer Engagement**: Loyalty program adoption up 15% to 44.3M members, with targeted marketing and rewards driving engagement. 
- **Productivity Initiatives**: $1.5B cost savings target over 3 years through supply chain automation (30% of distribution volume to be automated by 2025), AI-driven inventory management, and produce department efficiency improvements. 

**【CFO Financial Highlights】**
- **Q3 2024 Results**: 
  - ID Sales +2% (pharmacy +13%, digital +23%) 
  - Adjusted EBITDA: $1.065B (down 4% YoY) 
  - Adjusted EPS: $0.71 (down 10% YoY) 
  - Gross Margin: 27.9% (down 27bps YoY due to pharmacy mix and digital costs) 
- **2024 Outlook Update**: 
  - ID Sales: 1.8-2.0% growth (previously 1.8-2.2%) 
  - Adjusted EBITDA: $3.95-3.99B (up from $3.90-3.98B) 
  - Adjusted EPS: $2.25-2.31 (up from $2.20-2.28) 
  - Tax Rate: 15-16% (benefit from $81M audit settlement) 
- **Capital Allocation**: $1.8-1.9B in CapEx, $0.15Q1 dividend (+25%), and $2B share buyback authorization. 

**【Q&A Key Takeaways】**
- **Market Share & Competition**: Acknowledged mass retailers' growth but focused on digital engagement (e.g., 8M+ customers using in-store mobile features). 
- **Gross Margin Pressure**: Pharmacy and digital growth driving mix shift, offset by $1.5B productivity savings. 
- **Media Collective Growth**: Albertsons Media Collective (AMC) growing faster than market, with 4 digital platforms generating data for targeted campaigns. 
- **Store Optimization**: 30% of distribution volume to be automated by 2025, with focus on fresh quality and cost efficiency. 
- **GLP-1 Impact**: Pharmacy growth from GLP-1 scripts may negatively impact food volume trends, but long-term customer value outweighs short-term margin pressure. 


Albertsons Companies (ACI)-8 Jan 25-2025 Q3 Earnings call transcript

- **Revenue Growth**: 2.2% identical sales driven by 19% pharmacy and 23% e-commerce growth, with 48M loyalty members.
- **AI & Tech Investment**: Partnering with OpenAI to optimize merchandising, real estate, and operations.
- **Financial Strength**: $750M ASR announced, with FY25 EBITDA guidance of $3.8-3.9B and 2.2x debt/EBITDA.
- **Profitability Focus**: 50bps SG&A margin improvement, $1.5B+ productivity savings by 2027, and near-break-even e-commerce.

**【CEO Opening Remarks】**
- Emphasized a 'new day' at Albertsons, focusing on customer-centric innovation, AI-driven efficiency, and strategic investments in digital, media, and health solutions.
- Highlighted 2.2% identical sales growth, driven by pharmacy (19% YoY) and e-commerce (23% YoY), with 48 million loyalty members.
- Announced $750M accelerated share repurchase to return value to shareholders.

**【CFO Financial Commentary】**
- Q2 2025: Adjusted EBITDA of $848M, EPS of $0.44, and 50bps improvement in SG&A margin due to cost control.
- Updated FY25 outlook: Identical sales 2.2-2.75%, EBITDA $3.8-3.9B, EPS $2.16-2.19, and capex $1.8-1.9B for digital and automation.
- Gross margin pressured by digital/pharmacy mix but offset by productivity savings ($1.5B+ by 2027).

**【Q&A Highlights】**
- **E-commerce growth**: Near break-even with 30-minute delivery, leveraging store networks for last-mile efficiency.
- **Pharmacy strategy**: Gaining market share via GLP-1s and closures of 29 stores, with 19% YoY script growth.
- **AI adoption**: Partnering with OpenAI for merchandising, real estate analytics, and store operations optimization.
- **Capital allocation**: Prioritizing share buybacks (total $2.75B authorized) while maintaining 2.2x debt/EBITDA ratio.

ACI

ACI fundamentals

Earnings Call

You can ask Aime